PT1051187E - Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt) - Google Patents

Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)

Info

Publication number
PT1051187E
PT1051187E PT99903480T PT99903480T PT1051187E PT 1051187 E PT1051187 E PT 1051187E PT 99903480 T PT99903480 T PT 99903480T PT 99903480 T PT99903480 T PT 99903480T PT 1051187 E PT1051187 E PT 1051187E
Authority
PT
Portugal
Prior art keywords
lymphotoxin
treatment
follicular lymphomas
inhibitors
via inhibitors
Prior art date
Application number
PT99903480T
Other languages
English (en)
Inventor
Jeffrey Browning
Jeanette Thorbecke
Vincent Tsiagbe
Original Assignee
Biogen Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ New York filed Critical Biogen Inc
Publication of PT1051187E publication Critical patent/PT1051187E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT99903480T 1998-01-30 1999-01-29 Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt) PT1051187E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02

Publications (1)

Publication Number Publication Date
PT1051187E true PT1051187E (pt) 2004-03-31

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99903480T PT1051187E (pt) 1998-01-30 1999-01-29 Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)

Country Status (25)

Country Link
EP (1) EP1051187B9 (pt)
JP (2) JP4713733B2 (pt)
KR (1) KR100622960B1 (pt)
CN (1) CN1287853C (pt)
AT (1) ATE253930T1 (pt)
AU (1) AU752710B2 (pt)
BR (1) BR9908214A (pt)
CA (1) CA2319698A1 (pt)
CZ (1) CZ301026B6 (pt)
DE (1) DE69912743T2 (pt)
DK (1) DK1051187T3 (pt)
EA (1) EA003862B1 (pt)
EE (1) EE05235B1 (pt)
ES (1) ES2211035T3 (pt)
HK (1) HK1029944A1 (pt)
HU (1) HU226044B1 (pt)
IL (2) IL137489A0 (pt)
IS (1) IS2254B (pt)
NO (1) NO328116B1 (pt)
NZ (1) NZ506529A (pt)
PL (1) PL203279B1 (pt)
PT (1) PT1051187E (pt)
SK (1) SK285725B6 (pt)
TR (2) TR200101693T2 (pt)
WO (1) WO1999038525A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0012006A (pt) * 1999-06-28 2002-03-12 Basf Ag Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
AU2001238076A1 (en) 2000-02-11 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
TR200300478T2 (tr) 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
RU2320331C2 (ru) 2002-03-04 2008-03-27 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. Способ индукции конечной дифференцировки
AR040367A1 (es) 2002-07-01 2005-03-30 Biogen Inc Anticuerpos humanizados contra el receptor de linfotoxina beta
EP1531907A1 (en) * 2002-08-14 2005-05-25 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
JP2002501902A (ja) 2002-01-22
PL342063A1 (en) 2001-05-21
IL137489A (en) 2010-05-31
ES2211035T3 (es) 2004-07-01
EE200000446A (et) 2001-08-15
HUP0102363A2 (hu) 2001-10-28
CN1287853C (zh) 2006-12-06
SK11302000A3 (sk) 2001-01-18
IS5570A (is) 2000-07-21
ATE253930T1 (de) 2003-11-15
TR200002203T2 (tr) 2000-12-21
JP2010235621A (ja) 2010-10-21
CZ20002751A3 (cs) 2000-12-13
HUP0102363A3 (en) 2004-04-28
EP1051187B1 (en) 2003-11-12
IS2254B (is) 2007-06-15
JP4713733B2 (ja) 2011-06-29
EA003862B1 (ru) 2003-10-30
KR20010040497A (ko) 2001-05-15
PL203279B1 (pl) 2009-09-30
BR9908214A (pt) 2000-11-28
DE69912743T2 (de) 2004-09-23
CZ301026B6 (cs) 2009-10-14
HK1029944A1 (en) 2001-04-20
NO20003848D0 (no) 2000-07-27
AU2348899A (en) 1999-08-16
EE05235B1 (et) 2009-12-15
CN1289252A (zh) 2001-03-28
DE69912743D1 (de) 2003-12-18
HU226044B1 (en) 2008-03-28
IL137489A0 (en) 2001-07-24
AU752710B2 (en) 2002-09-26
KR100622960B1 (ko) 2006-09-12
EA200000798A1 (ru) 2001-02-26
EP1051187A1 (en) 2000-11-15
DK1051187T3 (da) 2004-03-08
WO1999038525A1 (en) 1999-08-05
NZ506529A (en) 2002-12-20
NO20003848L (no) 2000-10-02
SK285725B6 (sk) 2007-07-06
NO328116B1 (no) 2009-12-14
CA2319698A1 (en) 1999-08-05
EP1051187B9 (en) 2004-08-11
TR200101693T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
MY151032A (en) Treatment of tnf? related disorders
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
MY121548A (en) Compounds and methods for the treatment of cancer
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
UY26265A1 (es) Compuestos calciolíticos
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DE60029463D1 (de) Behandlung von dyskinesie
IL139144A0 (en) Mycobacterial inhibitors
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
AU2013204147B2 (en) Treatment of TNFalpha related disorders
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу